PDF(Pubmed)
Abstract：
Conditioning regimens employed in autologous stem cell transplantation have been proven useful in various hematological disorders and underlying malig nancies; however, despite being efficacious in various instances, negative consequences have also been recorded. Multiple conditioning regimens were extracted from various literature searches from databases like PubMed, Google scholar, EMBASE, and Cochrane. Conditioning regimens for each disease were compared by using various end points such as overall survival (OS), progression free survival (PFS), and leukemia free survival (LFS). Variables were presented on graphs and analyzed to conclude a more efficacious conditioning regimen. In multiple myeloma, the most effective regimen was high dose melphalan (MEL) given at a dose of 200/mg/m2. The comparative results of acute myeloid leukemia were presented and the regimens that proved to be at an admirable position were busulfan (BU) + MEL regarding OS and BU + VP16 regarding LFS. In case of acute lymphoblastic leukemia (ALL), BU, fludarabine, and etoposide (BuFluVP) conferred good disease control not only with a paramount improvement in survival rate but also low risk of recurrence. However, for ALL, chimeric antigen receptor (CAR) T cell therapy was preferred in the context of better OS and LFS. With respect to Hodgkin\'s lymphoma, mitoxantrone (MITO)/MEL overtook carmustine, VP16, cytarabine, and MEL in view of PFS and vice versa regarding OS. Non-Hodgkin\'s lymphoma patients were administered MITO (60 mg/m2) and MEL (180 mg/m2) which showed promising results. Lastly, amyloidosis was considered, and the regimen that proved to be competent was MEL 200 (200 mg/m2). This review article demonstrates a comparison between various conditioning regimens employed in different diseases.
摘要：
自体干细胞移植中使用的调理方案已被证明可用于各种血液系统疾病和潜在的malignancies；然而，尽管在各种情况下都有效，负面后果也已记录在案。从PubMed等数据库的各种文献检索中提取了多种调理方案，谷歌学者，EMBASE,还有Cochrane.通过使用各种终点（如总生存期（OS））比较每种疾病的预处理方案，无进展生存期（PFS），和无白血病生存（LFS）。变量在图表上显示并分析以得出更有效的调节方案。在多发性骨髓瘤中，最有效的方案是以200/mg/m2的剂量给予高剂量美法仑(MEL).提出了急性髓细胞性白血病的比较结果，被证明处于令人钦佩的方案是关于OS的白消安（BU）MEL和关于LFS的BUVP16。在急性淋巴细胞白血病（ALL）的情况下，BU,氟达拉滨,和依托泊苷（BuFluVP）不仅可以极大地改善生存率，而且可以降低复发风险。然而,对于所有人，在更好的OS和LFS的背景下,嵌合抗原受体(CAR)T细胞疗法是优选的.关于霍奇金淋巴瘤,米托蒽醌（MITO）/MEL超过卡莫司汀，VP16，阿糖胞苷，和MEL考虑到PFS，反之亦然。非霍奇金淋巴瘤患者给予MITO（60mg/m2）和MEL（180mg/m2），结果良好。最后,考虑到淀粉样变性，证明有效的方案是MEL200（200mg/m2）。这篇综述文章展示了在不同疾病中使用的各种调理方案之间的比较。
